Altimmune, Inc. 8-K

What Happened Altimmune, Inc. announced its financial results for the first quarter ended March 31, 2026 via a press release dated May 13, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02), which was signed by CFO Gregory Weaver on May 13, 2026.

Key Details

• Filing: Form 8-K filed May 13, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• Press release: Dated May 13, 2026 and furnished as Exhibit 99.1 to the 8-K.
• Reporting period: Quarterly results cover the quarter ended March 31, 2026.
• Authorized signatory: Report signed by Gregory Weaver, Chief Financial Officer, dated May 13, 2026.

Why It Matters This 8-K signals that Altimmune has publicly disclosed its latest quarterly results—key information for investors evaluating recent earnings, revenue trends, cash position, and any updated guidance. Retail investors should read the attached press release (Exhibit 99.1) for the specific financial figures and management commentary, since the 8-K itself furnishes that release rather than restating all details within the filing.